

## ZTlido<sup>™</sup> (lidocaine topical system) – New drug approval

- On February 28, 2018, <u>Sorrento Therapeutics and Scilex Pharmaceuticals announced</u> the FDA approval of <u>ZTlido (lidocaine topical system)</u> 1.8% for the relief of pain associated with post-herpetic neuralgia (PHN).
- Because of the difference in bioavailability of ZTlido compared to <u>Lidoderm<sup>®</sup> (lidocaine patch)</u> 5%, a
  different dosage strength is required to be administered to the patient. One ZTlido 1.8% topical
  system provides equivalent lidocaine exposure to one Lidoderm 5% patch.
- The efficacy of ZTlido was demonstrated in two clinical studies comparing lidocaine patch to vehicle patch in patients with PHN.
  - A study of 35 patients demonstrated that treatment with a single dose of lidocaine patch had improvements in pain intensity from 4 to 12 hours vs. those treated with vehicle patch.
  - A multi-dose study of 32 patients demonstrated that treatment with lidocaine patch had statistically significant differences in terms of time to exit from the trial (14 vs. 3.8 days, p < 0.001), daily average pain relief, and patient's preference of treatment vs. those treated with vehicle patch.
- ZTlido adhesion performance was demonstrated in a clinical study of 54 patients, where 87% had adhesion scores of 0 (≥ 90% adhered) for all evaluations performed every 3 hours during the 12 hours of administration, and 13% had adhesion scores of 1 (≥ 75% to < 90% adhered) for at least one evaluation, and no subjects had scores of ≥ 2 (< 75% adhered).
- ZTlido is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product.
- Warnings and precautions of ZTlido include accidental exposure, excessive dosing/overexposure to lidocaine, application site reactions, and eye exposure.
- Common adverse reactions associated with ZTlido use were application site reactions, such as irritation, erythema, and pruritus.
- The prescribed number of ZTlido topical systems should be applied to intact skin to cover the most painful area. A maximum of 3 topical systems may be used once for up to 12 hours within a 24-hour period (12 hours on and 12 hours off).
  - When ZTlido is used concomitantly with other products containing local anesthetic agents, the total amount of drug absorbed from all formulations must be considered.
  - Smaller areas of treatment are recommended in a debilitated patient, or a patient with impaired elimination.
  - Refer to the ZTlido prescribing information for further storage, application, removal, and disposal instructions.
- Sorrento Therapeutics and Scilex Pharmaceuticals plan to launch ZTlido in 2018. ZTlido will be available as a 1.8% topical system.



## optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2018 Optum, Inc. All rights reserved.